tradingkey.logo
tradingkey.logo
Search

Champions Oncology Inc

CSBR
Add to Watchlist
6.200USD
-0.110-1.74%
Close 05/15, 16:00ETQuotes delayed by 15 min
86.10MMarket Cap
LossP/E TTM

Champions Oncology Inc

6.200
-0.110-1.74%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-1.74%

5 Days

+2.99%

1 Month

+1.64%

6 Months

-8.82%

Year to Date

-10.27%

1 Year

-2.36%

Key Insights

Champions Oncology Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 184 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 12.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Champions Oncology Inc's Score

Industry at a Glance

Industry Ranking
184 / 382
Overall Ranking
340 / 4482
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Champions Oncology Inc Highlights

StrengthsRisks
Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
Growing
The company is in a growing phase, with the latest annual income totaling USD 56.94M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Undervalued
The company’s latest PE is -35.94, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 6.66M shares, decreasing 5.85% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 154.84K shares of this stock.

Analyst Rating

Based on 0 analysts
--
Current Rating
12.000
Target Price
+109.42%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Champions Oncology Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Champions Oncology Inc Info

Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
Ticker SymbolCSBR
CompanyChampions Oncology Inc
CEOBrainin (Robert)
Websitehttps://championsoncology.com
KeyAI